{
    "clinical_study": {
        "@rank": "56854", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the efficacy and safety of Avelox Tablet 400 mg\n      (hereinafter as \"Avelox\") in treating secondary infection of chronic respiratory disease.It\n      is a local prospective and observational study of patients who have received Avelox tablets\n      for Laryngopharyngitis, Tonsillitis, Bronchitis acute, Pneumonia, Secondary infection in\n      chronic respiratory diseases, Sinusitis. A total of 500 patients are to be enrolled and\n      assessed during the period of treatment with Avelox."
        }, 
        "brief_title": "Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Anti-Infective Agents", 
        "condition_browse": {
            "mesh_term": [
                "Respiration Disorders", 
                "Respiratory Tract Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with secondary infection of chronic respiratory disease (excluding acute\n             bronchitis patients who have been determined to be without chronic respiratory tract\n             disease based on their medical history, x-ray findings, and/or other findings) who\n             meet the following criteria:\n\n          -  20 years old or older\n\n          -  with infection of mild or moderate severity\n\n          -  Patients who meet the following criteria immediately before starting the therapy:\n             \u226537\u00b0C of body temperature, expectoration of purulent or mucopurulent sputum, and\n             either white blood cell count \u22658,000/mm3 or CRP \u22650.7 mg/dL\n\n        Exclusion Criteria:\n\n          -  Patients who are contraindicated based on the product label."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with secondary infection of chronic respiratory disease (excluding acute\n        bronchitis patients who have been determined to be without chronic respiratory tract\n        disease based on their medical history, x-ray findings, and/or other findings)"
            }
        }, 
        "enrollment": {
            "#text": "497", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690533", 
            "org_study_id": "16515"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated with Moxifloxacin in daily clinical practice", 
            "intervention_name": "Avelox (Moxifloxacin, BAY12-8039)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Avelox", 
            "Laryngopharyngitis", 
            "Tonsillitis", 
            "Bronchitis acute", 
            "Pneumonia", 
            "Secondary infection in chronic respiratory diseases Sinusitis"
        ], 
        "lastchanged_date": "September 17, 2013", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of adverse drug reactions (ADRs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days"
            }, 
            {
                "measure": "Clinical efficacy rate (Response, Minor Response, No Response and Indeterminable) assessed by investigator's discretion. Efficacy rate is calculated as number of patients with Response or Minor Response proportional to number of all cases.", 
                "safety_issue": "No", 
                "time_frame": "After 7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690533"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "ADR incidence rates classified by patient's background factors", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days"
            }, 
            {
                "measure": "Efficacy rates classified by patient's background factors", 
                "safety_issue": "No", 
                "time_frame": "After 7 days"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2008", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}